No Data
No Data
Bicara Therapeutics Initiated at Outperform by Wedbush
Wedbush Initiates Bicara Therapeutics(BCAX.US) With Buy Rating, Announces Target Price $31
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results With Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA), Acadia Healthcare (ACHC) and Bicara Therapeutics Inc. (BCAX)
Unlock the Full List